Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

High-dose flu shots inked to lower Alzheimer's dementia risk in older adults

2

Apr 2026

High-dose flu shots inked to lower Alzheimer's dementia risk in older adults

A large US claims-based study found that adults aged 65 and older who received a high-dose flu vaccine had a lower observed risk of Alzheimer dementia than those who received a standard-dose vaccine, with the association lasting up to 25 months in per-protocol analyses and 28 months in intention-to-treat analyses. The signal appeared stronger and more sustained in women, though the authors stress that the findings are observational and need confirmation in longer prospective studies.

Oral molecule prevents kidney stones and restores survival in mice

2

Apr 2026

Oral molecule prevents kidney stones and restores survival in mice

Scientists at the Buck Institute for Research on Aging have shown that an orally administered small molecule, N-propargylglycine (N-PPG), can completely prevent the formation of calcium oxalate kidney stones, protect against kidney failure, and fully restore normal survival in a mouse model of Primary Hyperoxaluria Type 2 (PH2), a rare and currently untreatable genetic disorder that causes progressive kidney failure in infants and young adults.

Sleep apnea raises risk of cardiovascular events and death

2

Apr 2026

Sleep apnea raises risk of cardiovascular events and death

New research to be presented at this year's European Congress on Obesity (ECO 2026, Istanbul, Turkey, 12-15 May) shows that those living with obstructive sleep apnea (OSA) have a 71% higher risk of cardiovascular events (CVEs) or death from any cause (all-cause mortality) compared with those not living with OSA.

Moderate wine intake tied to slower biological aging in men

2

Apr 2026

Moderate wine intake tied to slower biological aging in men

Researchers studying 22,495 adults in Southern Italy found that men with moderate wine intake in the traditional Mediterranean diet range showed slightly slower biomarker-based biological aging, with the lowest estimated aging signal at about 170 mL per day. The study also found that overall ethanol intake did not show the same moderate-level pattern, and higher total alcohol intake was linked to faster biological aging in dose-response analyses.

Obesity, sleep, smoking, and inactivity show the strongest links to hypertension in U.S. adults

2

Apr 2026

Obesity, sleep, smoking, and inactivity show the strongest links to hypertension in U.S. adults

A cross-sectional analysis of 20,912 U.S. adults found that obesity, overweight, inadequate physical activity, smoking, and short or long sleep were each associated with higher odds of hypertension, while overall diet quality by HEI-2015 was not significantly associated. Sleep associations differed by sex, and lower sodium intake remained linked to lower odds of hypertension in sensitivity analyses.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.